Showing results (1831-1840 of 1,949) with videos related to
Sort By:
Pageof 195
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor CellsFatma Aboulnasr, Ashton Krogman, Rondell P Graham, et al.BMC Medical Genomics|January 30, 2013
Multilocus loss of DNA methylation in individuals with mutations in the histone H3 lysine 4 demethylase KDM5CDaria Grafodatskaya, Barian H Y Chung, Darci T Butcher, et al.NPJ Genomic Medicine|December 22, 2017
De novo large rare copy-number variations contribute to conotruncal heart disease in Chinese patientsChristopher C Y Mak, Pak Cheong Chow, Anthony P Y Liu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2019
The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the LungAnthony W Chan, Shuk L Chau, Joanna H Tong, et al.Journal of Pain and Symptom Management|July 6, 2019
COMPASS: A Pilot Trial of an Early Palliative Care Intervention for Patients With End-Stage Liver DiseaseMyrick C Shinall, Mohana Karlekar, Sara Martin, et al.ACS Chemical Biology|November 11, 2011
Inhibition of hematopoietic protein tyrosine phosphatase augments and prolongs ERK1/2 and p38 activationEduard Sergienko, Jian Xu, Wallace H Liu, et al.Pharmacy (Basel, Switzerland)|December 22, 2019
A Quantitative and Narrative Evaluation of Goodman and Gilman's Pharmacological Basis of TherapeuticsBrian J Piper, Alexandria A Alinea, John R Wroblewski, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor PrognosisJoanna H Tong, Sai F Yeung, Anthony W H Chan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.Antimicrobial Agents and Chemotherapy|March 10, 2022
An Optimized Dihydrodibenzothiazepine Lead Compound (SBI-0797750) as a Potent and Selective Inhibitor of Plasmodium falciparum and P. vivax Glucose 6-Phosphate Dehydrogenase 6-PhosphogluconolactonaseIsabell Berneburg, Satyamaheshwar Peddibhotla, Kim C Heimsch, et al.Pageof 195